title: Response to measles revaccination among toddlers in Saudi Arabia by the use of two different trivalent measles-mumps-rubella vaccines.
abstract: This trial confirmed the immunogenicity of a standard dose of measles vaccine Edmonston-Zagreb strain administered at the age of 6 months as evaluated serologically at 12 months of age in 94 healthy children in Saudi Arabia. The residual seropositivity rate for measles was 53.4 and 80.6% as measured by enzyme immunoassay (EIA) and plaque neutralization, respectively, and could be increased to virtually 100% seroprotection after immunization with 1 of 2 measles-mumps-rubella (MMR) vaccines (Triviraten Berna or MMR II MSD) at 12 months of age. In both groups, more than 90% of infants showed an immune response to the mumps and rubella vaccine strains at 14 months of age. There was a difference in the geometric mean titres of mumps antibodies in favour of MMR II (P < 0.001). The seroconversion rates for mumps antibodies differed between the 2 vaccines because of the different test systems and/or the different cut-off levels used. The study reconfirmed that for the assessment of Rubini mumps vaccine-induced antibodies the indirect immunofluorescence test is superior to the EIA. The systemic tolerability of both vaccines was excellent. Triviraten Berna is exclusively propagated on human diploid cell cultures and hence free of avian proteins.
authors.affiliation: Suleimania Children's Hospital, Riyadh, Saudi Arabia.
authors.forename: M
authors.initials: M
authors.lastname: Khalil
authors.forename: A A
authors.initials: AA
authors.lastname: Poltera
authors.forename: M
authors.initials: M
authors.lastname: al-Howasi
authors.forename: C
authors.initials: C
authors.lastname: Herzog
authors.forename: E
authors.initials: E
authors.lastname: Gerike
authors.forename: B
authors.initials: B
authors.lastname: Wegmüller
authors.forename: R
authors.initials: R
authors.lastname: Glück
mesh_terms: D000914:Antibodies, Viral / Q000096:biosynthesis; D006801:Humans; D007124:Immunoenzyme Techniques; D007223:Infant; D008458:Measles Vaccine / Q000276:immunology*; D022542:Measles-Mumps-Rubella Vaccine; D009108:Mumps Vaccine / Q000276:immunology*; D009500:Neutralization Tests; D012411:Rubella Vaccine / Q000276:immunology*; D012529:Saudi Arabia; D013997:Time Factors; D017778:Vaccines, Combined / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; D008458:Measles Vaccine; D022542:Measles-Mumps-Rubella Vaccine; D009108:Mumps Vaccine; D012411:Rubella Vaccine; D017778:Vaccines, Combined